Abstract
Background:
The discovery of mutations in the epidermal growth factor receptor gene (EGFR) related to the clinical response to tyrosine kinase inhibitors, has transformed the management of non-small cell lung cancer (NSCLC). Several methods have been developed for determination of mutations in EGFR, with different sensitivity and potential ability to detect a different number of mutations.
Methods:
We developed a screening method by high resolution melting (HRM) to detect EGFR mutations, and compared the results of 123 fixed in formalin and paraffin embedded (FFPE) tumor tissue samples with the detection of mutations by allele-specific PCR. In samples with discordant results, Sanger and massive parallel sequencing (MPS) were additionally performed.
Results:
Eight samples showed discordant results between both methods. Three samples with negative results by allele specific PCR and positive by HRM were confirmed by Sanger sequencing (p.S768I+p.V769L, T751_I759del and p.E709K+p.G719A; patients 1, 3 and 4, respectively). One sample with a negative result by HRM, and positive by allele specific PCR (p.T790M; patient 2), was confirmed by Sanger sequencing. Additionally, two positive samples for a deletion in exon 19 by allele-specific PCR, were negative by Sanger sequencing and HRM (patients 2 and 5) and finally, two samples were negative by allele-specific PCR and positive by HRM and Sanger sequencing due to synonymous variants in exon 21.
Conclusions:
HRM is a good method for mutational screening in EGFR. It is able to detect any change in the sequence of exons 18–21, providing high cost/effectiveness, but samples with low tumor burden may produce false negatives results.
Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.
Research funding: None declared.
Employment or leadership: None declared.
Honorarium: None declared.
Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.
References
1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. Ca Cancer J Clin 2014;64:9–29.10.3322/caac.21208Search in Google Scholar PubMed
2. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Placlitaxel-carboplatin alone or with bevacizumab non-small cell lung cancer. N Engl J Med 2006;355:2542–50.10.1056/NEJMoa061884Search in Google Scholar PubMed
3. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsivenes of non small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129–39.10.1056/NEJMoa040938Search in Google Scholar
4. Giaccone G, Herbst RS, Manegold C, Scagliotti G, Rosell R, Miller V, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small cell lung cancer: a phase III trial-INTACT 1. J Clin Oncol 2004;22:777–84.10.1200/JCO.2004.08.001Search in Google Scholar PubMed
5. Maemondo M. Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010;362:2380–8.10.1056/NEJMoa0909530Search in Google Scholar PubMed
6. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massutti B, Felip E, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012;13:239–46.10.1016/S1470-2045(11)70393-XSearch in Google Scholar PubMed
7. Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Can 2007;7:169–81.10.1038/nrc2088Search in Google Scholar PubMed
8. Kobayashi S, Boggon TJ, Dayaram T, Jänne PA, Kocher O, Meyerson M, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005;352:786–92.10.1056/NEJMoa044238Search in Google Scholar PubMed
9. Suda K, Onozato R, Yatabe Y, Mitsudomi T. EGFR T790M mutation: a double role in lung cancer cell survival? J Thorac Oncol 2009;4:1–4.10.1097/JTO.0b013e3181913c9fSearch in Google Scholar PubMed
10. Wu JY, Yu CJ, Chang YC, Yang CH, Shih JY, Yang PC. Effectiveness of tyrosine kinase inhibitors on ̔uncommon̓epidermal growth factor receptor mutations of unknown clinical significance in nonsmall cell lung cancer. Clin Cancer Res 2011;17: 3812–21.10.1158/1078-0432.CCR-10-3408Search in Google Scholar PubMed
11. Yasuda H, Kobayashi S, Costa DB. EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications. Lancet Oncol 2012;13:e23–31.10.1016/S1470-2045(11)70129-2Search in Google Scholar PubMed
12. Ellison G, Zhu G, Moulis A, Dearden S, Speake G, McCormack R. EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples. J Clin Pathol 2013;66:79–89.10.1136/jclinpath-2012-201194Search in Google Scholar PubMed PubMed Central
13. Pao W. Ladanyi M: Epidermal growth factor receptor mutation testing in lung cancer: searching for the ideal method. Clin Cancer Res 2007;13:4954–5.10.1158/1078-0432.CCR-07-1387Search in Google Scholar PubMed
14. Sueoka N, Sato A, Eguchi H, Komiya K, Sakuragi T, Mitsuoka M, et al. Mutation profile of EGFR gene detected by denaturing high-performance liquid chromatography in Japanese lung cancer patients. J Cancer Res Clin Oncol 2007;133:93–102.10.1007/s00432-006-0144-2Search in Google Scholar PubMed
15. Querings S, Altmüller J, Ansén S, Zandr T, Seidel D, Gabler F, et al. Benchmarking of mutation diagnostics in clinical lung cancer specimens. PloS One 2011;6:e19601.10.1371/journal.pone.0019601Search in Google Scholar PubMed PubMed Central
16. Ellison G, Donald E, McWalter G, Knight L, Fletcher L, Sherwood J, et al. A comparison of ARMS and DNA sequencing for mutation analysis in clinical biopsy samples. J Exp Clin Cancer Res 2010;29:132.10.1186/1756-9966-29-132Search in Google Scholar PubMed PubMed Central
17. Dufort S, Richard MJ, Lantuejoul S, De Fraipont F. Pyrosequencing, a method approved to detect the two major EGFR mutations for anti EGFR therapy in NSCLC. J Exp Clin Cancer Res 2011;30:57.10.1186/1756-9966-30-57Search in Google Scholar PubMed PubMed Central
18. Borràs E, Jurado I, Hernan I, Gamundi MJ, Dias M, Martí I, et al. Clinical pharmacogenomic testing of KRAS, BRAF and EGFR mutations by high resolution melting analysis and ultra-deep pyrosequencing. BMC Cancer 2011;11:406.10.1186/1471-2407-11-406Search in Google Scholar PubMed PubMed Central
19. Nokoto K, Tsuta K, Takano T, Fukui T, Yokozawa K, Sakamoto H, et al. Detection of EGFR mutations in archived cytologic specimens of non-small cell lung cancer using high resolution melting analysis. Am J Clin Pathol 2007;126:608–15.Search in Google Scholar
20. Do H, Krypuy M, Mitchell PL, Fox SB, Dobrovic A. High resolution melting analysis for rapid and sensitive EGFR and KRAS mutation detection in formalin fixed paraffin embedded biopsies. BMC Cancer 2008;8:142.10.1186/1471-2407-8-142Search in Google Scholar PubMed PubMed Central
21. Takano T, Ohe Y, Tsuta K, Fukui T, Sakamoto H, Yoshida T, et al. Epidermal growth factor receptor mutation detection using high-resolution melting analysis predicts outcomes in patients with advanced non-small cell lung cancer treated with gefitinib. Clin Cancer Res 2007;13:5385.90.10.1158/1078-0432.CCR-07-0627Search in Google Scholar PubMed
22. Hu C, Liu X, Chen Y, Gong Y, Geng M, Bi L. Direct serum and tissues assay for EGFR mutation in non-small cell lung cancer by high-resolution melting analysis. Oncol Rep 2012;28:1815–21.10.3892/or.2012.1987Search in Google Scholar PubMed
23. Jing CW, Wang Z, Cao HX, Ma R, Wu JZ. High resolution melting analysis for epidermal growth factor receptor mutations in formalin-fixed paraffin-embedded tissue and plasma free DNA from non-small cell lung cancer patients. Asian Pac J Cancer Prev 2014:14:6619–23.10.7314/APJCP.2013.14.11.6619Search in Google Scholar PubMed
24. Gonzalez-Bosquet J, Calcei JS, Wei J, Garcia-Closas M, Sherman ME, Hewitt S, et al. Detection of somatic mutations by high-resolution DNA melting (HRM) analysis in multiple cancers. PLoS One 2011;6:e14522.10.1371/journal.pone.0014522Search in Google Scholar PubMed PubMed Central
25. Angulo B, Lopez-Rios F, Gonzalez D. A new generation of companion diagnostics: cobas BRAF, KRAS and EGFR mutation detection tests. Expert Rev Mol Diagn 2014;14: 517–24.10.1586/14737159.2014.910120Search in Google Scholar PubMed
26. Kimura H, Ohira T, Uchida O, Matsubayashi J, Shimizu S, Nagao T, et al. Analytical performance of the cobas EGFR mutation assay for Japanese non-small-cell lung cancer. Lung Cancer 2014;83:329–33.10.1016/j.lungcan.2013.12.012Search in Google Scholar PubMed
27. Lopez-Rios F, Angulo B, Gomez B, Mair D, Martínez R, Conde E. Comparison of molecular testing methods for the detection of EGFR mutations in formalin-fixed paraffin-embedded tissue specimens of non-small cell lung cancer. J Clin Pathol 2013;66:381–5.10.1136/jclinpath-2012-201240Search in Google Scholar PubMed PubMed Central
28. O‘Donnell P, Ferguson J, Shyu J, Current R, Rehage T, Tsai J, et al. Analytic performance studies and clinical reproducibility of a real-time PCR assay for the detection of epidermal growth factor receptor gene mutations in formalin-fixed paraffin-embedded tissue specimens of non-small cell lung cancer. BMC Cancer 2013;13:210.10.1186/1471-2407-13-210Search in Google Scholar PubMed PubMed Central
©2017 Walter de Gruyter GmbH, Berlin/Boston
